Balloon Pulmonary Angioplasty in Non-operable CTEPH Patients

Study Purpose

Balloon pulmonary angioplasty (BPA) emerged as a potential therapeutic option for non-operable patients with chronic thromboembolic pulmonary hypertension (CTEPH). The aim of this study was to evaluate the safety and efficacy of BPA in patients disqualified from surgery or suffered from persistent CTEPH despite pulmonary endarterectomy. This is a interventional study analyzing the benefits and the risk of BPA. Clinical evaluation, including: functional capacity, 6-minutes walking test, haemodynamics, biomarkers, cardiopulmonary exercise test, echocardiography, electrocardiography and QoL assessment with Short Form 36 (SF36) questionnaire was performed before the initiation therapy of BPA, and 3-6 months after last session of BPA.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages 18 Years and Over
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

  • - diagnosed with CTEPH according to ESC Guidelines.
  • - WHO functional capacity ≥ II.
- documented period of anticoagulation > 6 months after the episode of Pulmonary Embolism,

Exclusion Criteria:

- age < 18 years

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT02964390
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

N/A
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Department of Pulmonary Circulation and Thromboembolic Diseases, Medical Center for Postgraduate Med
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Marcin Kurzyna, MD,PhD
Principal Investigator Affiliation European Health Center Otwock
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Other
Overall Status Recruiting
Countries Poland
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Chronic Thromboembolic Pulmonary Hypertension
Additional Details

Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare but potentially life-threatening disease of the pulmonary circulation. Management of CTEPH requires precise differential diagnosis, long life anticoagulation when confirmed and qualification for surgical treatment by an experienced multidisciplinary team. The gold standard of treatment in operable patients is pulmonary endarterectomy (PEA), which is highly effective in restoring functional status and improving life expectancy. Nevertheless, even in the leading CTEPH referral centres almost 50% patients remain on medical treatment alone, with grim perspectives regarding life quality and expectancy. Recently, balloon pulmonary angioplasty (BPA) has emerged as a promising new interventional option in non-operable CTEPH. The development BPA was far from rapid. It took 13 years from the first case-report to the publication of a first series of 17 patients treated with BPA in Boston/US and another 13 years until the results of first European series of 20 patients has been reported from Oslo/Norway. In Poland BPA was started to perform in non-operable CTEPH patients in 2013, motivated by their expected poor prognosis, when compared to those to whom surgical PEA was offered. The aim of this study is an analysis of efficacy and safety of BPA procedure. The BPA is performed by two senior interventional specialist

  • - cardiologist and radiologist with extensive experience in coronary, pulmonary and general vessel interventions supported by perfusion nurse.
All patients undergoing BPA are given informed consent before the first BPA intervention. The limited experience with and experimental nature of BPA are emphasised to candidates. A standard BPA procedure is typically performed from the right femoral vein, with anticoagulation of unfractionated heparin in periprocedural period. A long (70 or 90 cm) sheath is introduced into the pulmonary trunk with support of pigtail catheter. Selective and super-selective catheterisation of lobar arteries, segmental and when appropriate subsegmental arteries is performed to demonstrate variety of clots: "webs", "rings", "occlusions", "pouch" lesions and reduction of parenchymal opacification after injection of vascular contrast medium. Balloon catheters (diameter 1.25-6.0 mm) are positioned over the selected lesion and dilated for several seconds. Immediate selective angiography is performed after dilation to confirm satisfactory results which presented the improvement of contrast medium distribution and venous return. Control angiography is done to rule out residual stenosis or signs of vessel injury. Following BPA procedure, patients are moved to ICU for 48 h surveillance. Right before the initiation of BPA and during 3-6 months after last session, a full workup is made, including: World Health Organization (WHO) functional class, 6-minute walking test (6MWT), concentration of biomarkers (NT-proBNP, Troponin T, sST2), cardiopulmonary exercise test, echocardiography, electrocardiography and right heart catheterization including measurements of right atrial pressure (RAP), pulmonary artery pressure (PAP), pulmonary capillary wedge pressure (PCWP), cardiac output (CO), cardiac index (CI), pulmonary vascular resistance (PVR), mixed venous oxygenation (MVsat.O2) and systemic oxygenation (AOsatO2). Additionally patients fill in the Short Form 36 (SF36) quality of life questionnaire before initiation of BPA and 3-6 months after last session.

Arms & Interventions

Arms

Experimental: Balloon Pulmonary Angioplasty

This arm includes patients qualified to BPA procedure. They have a baseline workup performed before the initiation of BPA treatment and had a follow up examination from 3 to 6 months after the last BPA session.

Interventions

Procedure: - Balloon Pulmonary Angioplasty

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

International Sites

European Health Center Otwock, Otwock, Poland

Status

Recruiting

Address

European Health Center Otwock

Otwock, , 05-400

Site Contact

Marcin Kurzyna, MD, PhD

marcin.kurzyna@ecz-otwock.pl

+48-22-7103052

For more information, please contact PHA at Research@PHAssociation.org and refer to the terms of service below.

Submit Feedback

The content provided on clinical trials is for informational purposes only and is not a substitute for medical consultation with your healthcare provider. We do not recommend or endorse any specific study and you are advised to discuss the information shown with your healthcare provider. While we believe the information presented on this website to be accurate at the time of writing, we do not guarantee that its contents are correct, complete, or applicable to any particular individual situation. We strongly encourage individuals to seek out appropriate medical advice and treatment from their physicians. We cannot guarantee the availability of any clinical trial listed and will not be responsible if you are considered ineligible to participate in a given clinical trial. We are also not liable for any injury arising as a result of participation in a clinical trial or study.